Mar 16, 2023 7:00am EDT Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
Mar 13, 2023 7:00am EDT Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
Feb 14, 2023 7:00am EST Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
Jan 24, 2023 7:00am EST Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
Jan 11, 2023 9:04am EST Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
Jan 10, 2023 7:00am EST Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
Dec 28, 2022 7:00am EST Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
Dec 08, 2022 7:00am EST Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis
Nov 25, 2022 7:00am EST Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
